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P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) 
expression are frequently related to multidrug resistance (MDR) in neoplastic cells. 
Canine inflammatory and grade III non-inflammatory mammary carcinomas (IMC and 
non-IMC) are aggressive tumors that could benefit from chemotherapy. This study 
describes the immunohistochemical expression of P-gp and BCRP in 20 IMCs and 
18 non-IMCs from dogs that had not received chemotherapy. Our aim was to 
determine if P-gp and BCRP expression were related to the “inflammatory” 
phenotype, to establish a basis for future studies analyzing the response to 
chemotherapy in dogs with highly malignant mammary cancer. Immunolabeling was 
primarily membranous for P-gp with a more intense labeling in emboli, and 
immunolabeling was membranous and cytoplasmic for BCRP. IMCs expressed P-gp 
in 17/20 (85%) cases while 7/18 (39%) non-IMCs expressed P-gp, with a significant 
higher number of IMCs versus non-IMCs (P=0.006). BCRP was expressed within 
emboli in  15/19 (79%) emboli in IMC, 12/15 (80%) primary IMC and 12/18 (67%) 
non-IMC, without statistically significant differences (P>0.05). All IMCs and 67% of 
non-IMCs expressed at least one of the two transporters, and 63% (12/19) of IMC 
and 39% (7/18) of non-IMC expressed both P-gp and BCRP. P-gp and BCRP 
evaluation could help select patients for chemotherapy. P-gp, expressed in a 
significantly higher percentage of IMC vs non-IMC, could play a specific pathogenic 
role in the chemoresistance of IMC.  
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P-gp and BCRP are well-known adenosine triphosphate-binding cassette (ABC)-
transporter efflux pumps influencing chemotherapy resistance in cancer. Due to their 
capacity to export a wide variety of cell substrates, including many of the currently 
available chemotherapeutic compounds, the pumps prevent the intracellular action of 
these drugs.20 De novo or intrinsic multidrug resistance (MDR) occurs in a tumor 
when ABC-transporters such as P-gp and BCRP are expressed and functional in 
neoplastic cells before induction chemotherapy, while secondary or acquired 
expression of ABC-transporters appears after the first chemotherapy treatment.10 P-
gp and BCRP are also considered markers of the so-called side population of cancer-
initiating cells. Because of this, the regulation of stem cell biology by ABC-
transporters has emerged as an important new field of investigation. The complex 
role of P-gp and BCRP in breast cancer has been addressed in human research,14,34 
whereas data on the role of chemoresistance mediated by ABC-transporters in 
veterinary oncology are currently scant.,30,68 
Canine mammary neoplasia comprises a group of tumors with heterogeneous 
pathological phenotypes and clinical behavior.,55 Carcinomas of the bitch are 
classified into three different histological grades of malignancy according to the most 
recent system.50 Histological grade III carcinomas are the rarest and have the worst 
prognosis with 71% of cancer-related death and/or recurrence/metastasis within a 28 
months follow-up period.50 Based on the limited clinical information available in 
veterinary medicine, the drugs effective in human breast cancer, such as 
cyclophosphamide, 5-fluorouracil, and doxorubicin, have been translated into 
veterinary oncology in an attempt to treat canine mammary carcinoma (CMC).19,27,60 
Treatment guidelines for malignant canine mammary gland tumors have been 
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proposed,60 but the administration of a chemotherapeutic regimen to dogs with 
aggressive CMC has yielded conflicting results.3,21,26,27,34,40,59,62  
Human inflammatory breast cancer (IBC) and its counterpart in the dog, canine 
inflammatory mammary cancer (IMC), are considered the most malignant mammary 
tumors.17,41,51,52,56,57,64IBC and IMC are clinicopathological entities diagnosed on the 
basis of a rapid progression of signs, dermal erythema, induration and edema of the 
mammary region, with the histological feature of massive embolization of neoplastic 
cells in superficial dermal lymphatic vessels.52,56,64 This neoplasm bears a unique 
rapid-growing, angioinvasive and angiogenic phenotype, which is far from being 
completely understood.17,29  
The therapeutic approach in women with IBC usually involves neoadjuvant 
anthracycline- and taxane-based chemotherapy, associated when feasible with 
ablative surgery and locoregional radiotherapy.6,22,61,64,65 Despite recent advances in 
multimodality treatments, the prognosis for women with IBC is still poor, with a 
median disease-free survival of less than 2.5 years.29,66 One study on medical 
treatment for dogs with IMC suggests a beneficial effect of nonsteroidal anti-
inflammatory drugs like piroxicam as a single-agent;37 in another study, the 
administration of piroxicam combined with either carboplatin, doxorubicin, 
capecitabine or cisplatin showed some improvement in prolonging survival time but 
without statistical significance.41 New therapeutic strategies to improve survival are 
needed in both species. Chemotherapeutic molecules like anthracycline are 
substrates of many ABC-transporters, and the onset of chemoresistance to these 
compounds has been attributed to the expression of P-gp and BCRP in human 
oncology.14,45,47 Some studies on canine mammary tumors have investigated P-gp 
and BCRP expression,4,16,25,28,32,33,49,53 but the role of these chemoresistance 
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modulators is still incipient. A previous study designed and carried out by some of the 
present study’s authors (ML, BB, GS, CB) evaluated the immunohistochemical 
expression of P-gp and BCRP in a cohort of canine mammary hyperplasia and 
benign and malignant mammary tumors.35  In that study, 22/47 (47%) of hyperplastic 
mammary lesions expressed P-gp, and 27/45 (60%) of these lesions were BCRP 
positive. However, P-gp and BCRP were most commonly expressed in malignant 
mammary tumors with 35/46 (77%) of the cases being P-gp positive and 36/44 (82%) 
of the cases being BCRP-positive, while only 4/10 (40%) of adenomas expressed P-
gp-positive and 2/10 (20%) expressed BCRP.35 Other studies have reported that 
these chemoresistance markers are more frequently expressed in aggressive 
mammary tumors compared to their benign counterparts.16,32,48,53 
Hence, the present study focused on a cohort of aggressive canine mammary tumors 
that included 20 IMCs and 18 grade III non-inflammatory mammary carcinomas (non-
IMCs) of different histological types from dogs that had not received chemotherapy. 
The goal of this study was to investigate if expression of these molecules was 
significantly associated with the “inflammatory” phenotype and to establish a basis for 
future studies analyzing the response to chemotherapy of canine patients with highly 
malignant mammary cancer. As canine mammary tumors, especially IMC and other 
invasive carcinomas, have been proposed as useful spontaneous models for 
studying their human counterparts,1,9,37,46,51,52,54 a better understanding of their 
biological behavior and chemoresistant phenotype would be helpful in both human 
and veterinary oncology. 
 
Materials and Methods 
Samples and histopathology 
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Samples were retrieved from the archive of the Veterinary Pathology Service, 
Veterinary Teaching Hospital, Complutense University of Madrid, Spain. According to 
the reports, the dogs had not received chemotherapy at the time of biopsy. Thirty-
eight formalin-fixed and paraffin-embedded tissue samples of mammary gland from 
38 dogs were selected based on the clinical and histopathological diagnoses of IMC 
and histologic grade III non-IMC. Carcinomas were graded according to the system 
proposed by Peña and colleagues (2013).50 In cases of IMC, the primary mammary 
carcinoma was included in the study when available (n=15). All primary IMCs were 
histological grade III. 
IMC diagnosis was based on the typical clinical presentation (with dermal erythema 
and edema in the ventral abdominal dermis), histologically associated with neoplastic 
emboli in superficial dermal lymphatic vessels. IMC emboli were detectable in each 
case (20/20), while the corresponding primary IMC was available in 15 cases. 
Hematoxylin and eosin-stained slides were histopathologically examined and when 
necessary the original diagnosis was updated according to the current histologic 
classification proposed by Goldschmidt and colleagues.18 Only grade III carcinomas 
were included in the study.  
Immunohistochemical expression of P-gp and BCRP 
Paraffin blocks were sectioned (3 μm) and placed in a PT module (Lab Vision) 
containing EDTA buffer solution (pH 8.0) (Master Diagnostica, MAD-004072R/D), 
heated for 20 minutes at 95°C and cooled to 60°C (dewaxing and antigen retrieval). 
Slides were rinsed in warm tap water and placed in an automated immunostainer 
(Lab Vision Corporation, Fremont, CA, USA) for immunohistochemistry. Slides were 
incubated for 120 minutes at room temperature with the following primary antibodies: 
mouse monoclonal anti-P-gp/CD243 (C494, GTX23365; Manufacturer: Gene Tex 
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International; dilution 1:1500) and mouse monoclonal anti-BCRP (BXP-21, Millipore-
MAB4146; manufacturer: Merck - dilution 1:200). Immunolabeling was detected with 
the peroxidase Master Polymer Plus Detection System, (Master Diagnostica, MAD-
000237QK) and, subsequently, the slides were counterstained with Mayer’s 
hematoxylin and permanently mounted with DPX mountant. External (normal canine 
liver) and internal (endothelium of blood and lymphatic vessels) positive controls for 
P-gp and BCRP were used. The cell membrane of hepatocytes (especially at the 
biliary canaliculi level), biliary epithelial cells and endothelial cells are normally 
labeled by both anti-Pgp and anti-BCRP antibodies and these served as  positive 
controls.   
Corresponding negative control slides were processed in parallel by replacing the 
primary antibody with non-reactive antibody. P-gp and BCRP immunolabeling was 
considered positive when >20% and >10% of cells were labeled for P-gp and BCRP, 
respectively, as suggested by previous studies.13,35,53 A further semiquantitative 
evaluation of the immunostaining was performed and the positive carcinomas were 
assigned to 2 subgroups according to the percentage of positive cells: intermediate 
positivity (range of 20-50% of P-gp-positive cells; range of 10-50% of BCRP-positive 
cells) or high positivity (>50% of P-gp-positive cells; >50% of  BCRP positive cells). 
One case of IMC with no available primary tumor was excluded from the evaluation 
of immunolabeling with anti-BCRP antibody because the internal control did not show 
the expected immunoreactivity with BCRP, probably due to antigen denaturation by 
overfixation. The selected samples included 20 IMCs and 18 non-IMCs. 
Statistical analysis 
P-gp and BCRP expression were compared by Fisher's exact method (GraphPad 
Software, La Jolla, California, USA; accessed May 2017). In IMCs, neoplastic cell 
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emboli were evaluated separately from the primary tumor and compared to each 
other. P-gp expression was evaluated in IMC emboli versus non-IMC, primary IMC 
versus non-IMC. BCRP expression was evaluated in IMC emboli versus non-IMC, 
primary IMC versus non-IMC. P <0.05 was considered significant.  
 
Results 
In the 15 IMCs for which the primary carcinoma was available, histotypes of the 
primary IMCs included 6 micropapillary invasive carcinomas, 3 comedocarcinomas, 2 
lipid-rich carcinomas, 2 solid carcinomas, 1 adenosquamous and 1 anaplastic 
carcinoma. Five cases of IMC did not have evidence of an associated primary 
mammary carcinoma; these samples where composed of dermal incisional biopsies 
(4 were sampled at necropsy, and 1 was submitted for histologic evaluation by a 
private practitioner) and histologically had massive embolization by neoplastic cells in 
dermal lymphatic vessels. In 8 cases of IMC, the embolized lymphatic vessels were 
surrounded by desmoplasia, often accompanied by severe dermal edema. Only 2 
cases showed multifocal areas of intratumor colliquative necrosis, while another 2 
cases had abundant inflammatory infiltrates of neutrophils, lymphocytes and plasma 
cells associated with the neoplasia.  
Histotypes of non-IMC included 7 solid carcinomas, 5 micropapillary invasive 
carcinomas, and 1 each of carcinoma mixed type, tubulopapillary carcinoma, 
comedocarcinoma, anaplastic carcinoma, adenosquamous carcinoma, and 
carcinoma and malignant myoepithelioma. Eight cases of non-IMC showed multifocal 
areas of colliquative necrosis in more than 50% of the tumor. Examples of IMC and 
non-IMC histotypes are shown in Supplemental Figures S1-S4. 
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The diffuse membranous immunolabeling of canine normal liver, the positive control 
for P-gp and BCRP, is shown in Supplemental Figures S7-S8, while the negative 
controls are shown in Supplemental Figures S9-S10. 
In tumor cells, P-gp immunolabeling was mainly membranous (Figure 1) and was 
particularly strong in neoplastic emboli of IMC (Figure 2). IMC emboli had cells with 
peculiar morphological features of severe anisokaryosis and anisocytosis. Some 
tumor cells stood out for their endothelial-like morphology, characterized by a rim of 
elongated cytoplasm containing extended eccentric nuclei encircling an empty round 
space and suggestive of vasculogenic mimicry. These cells were intensely 
immunolabeled for P-gp (Figures 3 and 4). BCRP showed membranous and 
cytoplasmic immunolabeling (Figures 5 and 6). Considering IMCs and non-IMCs 
together, P-gp was expressed in 24/38 (63%) tumors, and BCRP was expressed in 
27/37 (73%) tumors. IMCs expressed P-gp in lymphatic emboli in 17/20 (85%) cases, 
and in 12/15 (80%) primary IMCs. Fewer non-IMCs (7/18, 39%) expressed P-gp. P-
gp expression was significantly higher in emboli of IMC versus non-IMC (P=0.006) 
and in primary IMC vs non-IMC (P=0.032) (Supplemental Figure S5).  
 
BCRP was expressed in 15/19 (79%) IMC emboli, 12/15 (80%) primary IMC, and 
12/18 (67%) non-IMC (Supplemental Figure S6). There was no significant difference 
in BCRP expression between IMC and non-IMC.  
Co-expression of P-gp and BCRP in the same tumor is summarized in Table1.  
Considering IMCs, 12/19 (63%) emboli expressed both P-gp and BCRP, and all IMCs 
expressed at least one of the transporters (Figures 7a and 7b). Considering non-
IMCs, 7/18 (39%) expressed both P-gp and BCRP, and 12/18 (67%) expressed at 
least one of the transporters. 
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Non-IMC lacking both P-gp and BCRP expression included 2 solid, 2 micropapillary 
invasive, 1 adenosquamous, and 1 tubulopapillary carcinomas. 
Considering the subgrouping of the positive carcinomas, IMCs showed mostly a high 
number of positive cells for both transporters (>50% P-gp-positive cells in 11/17 of 
positive cases; >50% of BCRP-positive cells in 9/15 positive cases). Of the 7 P-gp-
positive primary non-IMCs, 3 contained between 20-50% of P-gp positive cells and 4 
cases had >50% P-gp positive cells.  Of the 12 BCRP-positive primary non-IMC 
cases, 3 had a between 10-50% BCRP-positive cells and 9 had >50% BCRP-positive 
cells. 
   
Discussion 
This is the first study to compare the expression of chemoresistance-associated 
markers P-gp and BCRP in canine grade III inflammatory (IMC) and comparable 
grade III non-inflammatory mammary carcinomas (non-IMC). These two uncommon 
tumor groups are biologically aggressive, especially IMC, and hence are potentially 
suitable for chemotherapy.  
This study presents a valuable caseload as it comprises rare neoplasms. The 
histological malignancy of the cases selected is represented not only by the high 
grade (grade III) but also by numerous highly malignant histotypes: micropapillary 
invasive carcinomas (6/20 cases) and comedocarcinomas (3/20 cases) in the IMC 
group; micropapillary invasive carcinomas (5/18) and solid carcinomas (7/18) among 
the non-IMCs. Comedocarcinoma and solid carcinoma have been recently defined as 
histotypes bearing a poor prognosis.55 
P-gp and BCRP both seem to significantly contribute tomultidrug resistance in human 
oncology.14,15,34 According to human breast cancer literature, chemoresistance 
12 
 
associated with P-gp and BCRP expression in tumors not subjected to chemotherapy 
at the time of biopsy is presumably an intrinsic phenomenon and ABC-transporters’ 
expression by neoplastic cells may lead to the failure of induction chemotherapy from 
the start. 10 
P-gp expression is the most widely studied mechanism of chemoresistance in breast 
cancer.11,12,36,42,44,63 About 40% of breast cancers express P-gp and its expression 
after exposure to chemotherapeutic drugs known to be P-gp substrates is correlated 
with a worse response to treatment in both the adjuvant and neoadjuvant 
settings.11,31,58,63 
Studies on P-gp expression in canine mammary tumors have reported P-gp protein, 
or MDR-1 mRNA, and its correlation with general clinical parameters.5,16,30,32,35,53 P-
gp expression varied from 76% to 50%.4,53  Increased P-gp expression has been 
found in canine mammary carcinomas compared with adenomas, and most authors 
agree that this finding is linked to the degree of tumor malignancy.4,32,35,53 
The present study found that IMCs expressed P-gp in 85% of emboli and in 80% of 
primary carcinomas, whereas this transporter was expressed in 38% of non-IMCs. 
Therefore, immunohistochemistry (IHC) can detect P-gp expression in both non-IMCs 
and IMC. The higher percentage of P-gp positive cases (63%) in the present study 
compared to that of Petterino et al. could be explained by the fact that we included 
IMCs and grade III non-IMCs that are very aggressive, a feature related to a higher 
expression of chemoresistance markers.32,53 
The chemoresistance marker BCRP has been reported to be expressed in breast 
cancer and has been correlated with resistance to 5-fluorouracil.8,13,38,39,45,67 Few 
studies are available on BCRP expression in canine mammary tumors.25,35,48,49 
Interestingly, BCRP was reportedly expressed in all canine tumor cell lines examined 
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and thus it was suggested that since BCRP induces resistance to doxorubicin, 
treating canine mammary tumors with doxorubicin should be considered with 
caution.25 Other IHC studies found a high percentage of neoplastic cells expressing 
BCRP and a positive correlation with the degree of canine mammary tumor 
malignancy.35,48 The present study found BCRP expressed in 79% of IMC emboli, 
80% of primary IMC and 67% of non-IMC. These findings are in accordance with the 
literature reporting that aggressive canine mammary tumors often display resistance 
to chemotherapeutic drugs, and that the administration of BCRP substrates should 
be carefully considered.  
Another interesting finding in the present study is that all IMCs expressed at least one 
of the two pumps, while 63% of IMCs and 39% of non-IMCs coexpressed both BCRP 
and P-gp.  This suggests these tumors are likely capable of developing resistance 
towards substrates of both P-gp and BCRP, bearing a more complex multidrug 
resistance phenotype. Expression of more than one ABC-transporter mRNA by the 
same tumor has been described in 56% of 103 canine mammary tumorswhere seven 
ABC-transporters, including P-gp and BCRP, were coexpressed. P-gp and BCRP 
were expressed in 92% and 100% of the tumors, respectively.25 These findings 
suggest caution when substrates of P-gp and BCRP (i.e. doxorubicin, vincristine, 
mitoxantrone) are prescribed in the treatment of IMC and non-IMC and canine 
mammary gland tumors. The routine evaluation of P-gp and BCRP expression may 
be potentially useful to select patients for chemotherapy as some human patients 
appear to have a naturally more aggressive phenotype associated with high levels of 





The expression of P-gp and BCRP seems to be common in dogs with highly 
malignant non-IMC and IMC. Caution is therefore required when administering 
substrates of P-gp and BCRP, because these tumors may bear chemoresistance 
towards these drugs. Routine evaluation of MDR marker expression may serve to 
select patients for chemotherapy. 
Future prospective studies are needed to demonstrate the association between 
chemoresistance and the expression of MDR markers in canine mammary cancer, 
and to shed more light on the complexity of its pathogenic mechanisms. This will 
serve to devise adequate patient-tailored chemotherapy protocols. Spontaneous 
canine IMC could represent a model to help understand its human counterpart, IBC, 
an understudied entity to date. 
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Figure 1-4. Canine inflammatory mammary 
cancer (IMC), mammary gland, dog. IHC for 
P-gp. Figure 1. Intense membranous 
expression of P-gp in neoplastic cells of a 
primary IMC. Figure 2. Emboli of IMC with 
intense membranous expression of P-gp. The 
endothelium of lymphatic vessel, considered a positive internal control, is positive. 
Figures 3-4. IMC, mammary gland, dog. Intense immunolabeling with P-gp of 
neoplastic cells with morphological features suggestive of vasculogenic mimicry.   
 
Figure 5-7. Mammary gland, dog. IHC for 
BCRP and P-gp. Figure 5. IMC. Intense 
membranous expression of BCRP in emboli of 
IMC in superficial dermal lymphatic vessels. 
The endothelium of lymphatic vessel, 
considered a positive internal control, is 
positive. Figure 6. Canine non-IMC histologic grade III mammary carcinoma, 
tubulopapillary histotype. Intense cytoplasmic and membranous expression of BCRP 
in neoplastic cells. Figure 7. Embolus of mammary inflammatory carcinoma. 
Neoplastic cells, in the same area, express both P-gp (Figure 7a) and BCRP (Figure 
7b), with  strong P-gp and mderate BCRP membranous immunolabeling and minimal 





Supplemental material figure legends 
Figure S1-2. Canine inflammatory mammary 
cancer (IMC), mammary gland, dog. Figure 
S1. Massive embolization of neoplastic cells 
in superficial dermal lymphatic vessels (inset 
at higher magnification), associated with 
interstitial dermal edema and moderate 
inflammatory infiltrate. HE. Figure S2. Primary IMC of micropapillary invasive 
histotype. HE. Figure S3-4. Canine non-inflammatory histologic grade III mammary 
carcinoma, mammary gland, dog. Figure S3. Solid histotype. HE. Figure S4. 
Adenosquamous histotype. HE. 
 
Figure S5. P-gp expression in neoplastic emboli 
(emboli IMC) and primary (primary IMC) tumor of 
canine inflammatory mammary cancer (IMC), and 
canine non-inflammatory histologic grade III 
mammary carcinoma (non-IMC). Emboli of IMC 
expressed P-gp in 85% of the cases (17/20), and primary IMC expressed P-gp in 
80% of the primary IMCs (12/15). Fewer cases of non-IMCs expressed P-gp (7/18, 
38.89%).  
Figure S6. BCRP expression in neoplastic emboli 
(emboli IMCe) and primary (primary IMCp) tumor of 
canine inflammatory mammary cancer (IMC), and 
canine non-inflammatory histologic grade III 
mammary carcinoma (non-IMC). BCRP was 
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expressed in 78.95% of IMC emboli (15/19), 80% of primary IMC (12/15) and 66.67% 
of non-IMC (12/18). 
Figure S7. Liver, dog. IHC for P-gp.  Intense 
P-gp immunolabelling of the plasma 
membranes of the hepatocytes, biliary 
epithelium and endothelial cells of hematic 
and lymphatic vessels in the positive control .  
Figure S8. Liver, dog. IHC for BCRP. 
Intense BCRP immunolabelling of the plasma membranes of the hepatocytes, biliary 
epithelium and endothelial cells of hematic and lymphatic vessels in the positive 
control. Figure S9. Liver, dog. IHC. P-gp expression in the negative control. Positive 
immunolabeling is absent. Figure S10. Liver, dog. IHC.BCRP expression in the 
negative control. Positive immunolabeling is absent.  
 
 
